Related references
Note: Only part of the references are listed.Metabolic Signature Identifies Novel Targets for Drug Resistance in Multiple Myeloma
Patricia Maiso et al.
CANCER RESEARCH (2015)
Acetyl Coenzyme A: A Central Metabolite and Second Messenger
Federico Pietrocola et al.
CELL METABOLISM (2015)
Antileukemic Activity of 2-Deoxy-D-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations
Clement Larrue et al.
MOLECULAR CANCER THERAPEUTICS (2015)
Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication
Hakon Reikvam et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer
Teraneh Z. Jhaveri et al.
ONCOTARGET (2015)
Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia
Pierre Sujobert et al.
CELL REPORTS (2015)
Role of Microenvironment in Resistance to Therapy in AML
Yoko Tabe et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2015)
Differential effects of AMPK agonists on cell growth and metabolism
E. E. Vincent et al.
ONCOGENE (2015)
A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value
Wen-Lian Chen et al.
BLOOD (2014)
Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect
Hakon Reikvam et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Small Molecule Drug A-769662 and AMP Synergistically Activate Naive AMPK Independent of Upstream Kinase Signaling
John W. Scott et al.
CHEMISTRY & BIOLOGY (2014)
Use of Metformin Alone Is Not Associated with Survival Outcomes of Colorectal Cancer Cell but AMPK Activator AICAR Sensitizes Anticancer Effect of 5-Fluorouracil through AMPK Activation
Xinbing Sui et al.
PLOS ONE (2014)
Apoptotic Efficacy of Etomoxir in Human Acute Myeloid Leukemia Cells. Cooperation with Arsenic Trioxide and Glycolytic Inhibitors, and Regulation by Oxidative Stress and Protein Kinase Activities
Maria Cristina Estan et al.
PLOS ONE (2014)
Surviving change: the metabolic journey of hematopoietic stem cells
Latika Kohli et al.
TRENDS IN CELL BIOLOGY (2014)
Synergistic anti-tumor activity of acadesine (AICAR) in combination with the anti-CD20 monoclonal antibody rituximab in in vivo and in vitro models of mantle cell lymphoma
Arnau Montraveta et al.
ONCOTARGET (2014)
A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors
Luis E. Raez et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
Acadesine for patients with relapsed/refractory chronic lymphocytic leukemia (CLL): a multicenter phase I/II study
Eric Van Den Neste et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
The metabolic perturbators metformin, phenformin and AICAR interfere with the growth and survival of murine PTEN-deficient T cell lymphomas and human T-ALL/T-LL cancer cells
Celia Rosilio et al.
CANCER LETTERS (2013)
Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells
Shanshan Pei et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2013)
From Gene Engineering to Gene Modulation and Manipulation: Can We Prevent or Detect Gene Doping in Sports?
Giuseppe Fischetto et al.
SPORTS MEDICINE (2013)
Emerging Metabolic Targets in the Therapy of Hematological Malignancies
Zaira Leni et al.
BIOMED RESEARCH INTERNATIONAL (2013)
The combination of valproic acid, all-trans retinoic acid and low-dose cytarabine as disease-stabilizing treatment in acute myeloid leukemia
Hanne Fredly et al.
CLINICAL EPIGENETICS (2013)
Targeting the AMP-activated pro prevention and therapy
In Young Kim et al.
FRONTIERS IN ONCOLOGY (2013)
Inhibition of Akt Potentiates 2-DG-Induced Apoptosis via Downregulation of UPR in Acute Lymphoblastic Leukemia
Joanna DeSalvo et al.
MOLECULAR CANCER RESEARCH (2012)
Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation
Eva Calvino et al.
BIOCHEMICAL PHARMACOLOGY (2011)
Antileukemic effects of AMPK activators on BCR-ABL-expressing cells
Eliza Vakana et al.
BLOOD (2011)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome
Patries M. Herst et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2011)
Therapeutic Efficacy and Safety of Paclitaxel/Lonidamine Loaded EGFR-Targeted Nanoparticles for the Treatment of Multi-Drug Resistant Cancer
Lara Milane et al.
PLOS ONE (2011)
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
Hartmut Doehner et al.
BLOOD (2010)
The LKB1/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation
Alexa S. Green et al.
BLOOD (2010)
AICAR induces apoptosis independently of AMPK and p53 through up-regulation of the BH3-only proteins BIM and NOXA in chronic lymphocytic leukemia cells
Antonio F. Santidrian et al.
BLOOD (2010)
The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
Patrick S. Ward et al.
CANCER CELL (2010)
AMPK as a metabolic tumor suppressor: control of metabolism and cell growth
Zhijun Luo et al.
FUTURE ONCOLOGY (2010)
Curcumin Stimulates Reactive Oxygen Species Production and Potentiates Apoptosis Induction by the Antitumor Drugs Arsenic Trioxide and Lonidamine in Human Myeloid Leukemia Cell Lines
Yolanda Sanchez et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Energy metabolism of leukemia cells: glycolysis versus oxidative phosphorylation
Kazuto Suganuma et al.
LEUKEMIA & LYMPHOMA (2010)
Targeting Tumor Metabolism With 2-Deoxyglucose in Patients With Castrate-Resistant Prostate Cancer and Advanced Malignancies
Mark Stein et al.
PROSTATE (2010)
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
Alberto M. Martelli et al.
ONCOTARGET (2010)
AMPK and the biochemistry of exercise: implications for human health and disease
Erik A. Richter et al.
BIOCHEMICAL JOURNAL (2009)
Abnormalities in Glucose Uptake and Metabolism in Imatinib-Resistant Human BCR-ABL-Positive Cells
Douglas J. Kominsky et al.
CLINICAL CANCER RESEARCH (2009)
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Matthew G. Vander Heiden et al.
SCIENCE (2009)
The Warburg effect: Why and how do cancer cells activate glycolysis in the presence of oxygen?
Miguel Lopez-Lazaro
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2008)
Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Xu Huang et al.
BIOCHEMICAL JOURNAL (2008)
Tumor cell metabolism: Cancer's Achilles' heel
Guido Kroemer et al.
CANCER CELL (2008)
Cancer cell metabolism: Warburg and beyond
Peggy P. Hsu et al.
CELL (2008)
The anti-trypanosomal agent lonidamine inhibits Trypanosoma brucei hexokinase 1
Jeremy W. Chambers et al.
MOLECULAR AND BIOCHEMICAL PARASITOLOGY (2008)
Hypoxia, HIF1 and glucose metabolism in the solid tumour
Nicholas C. Denko
NATURE REVIEWS CANCER (2008)
Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways
Jerome Tamburini et al.
BLOOD (2008)
Mechanism of action of A-769662, a valuable tool for activation of AMP-activated protein kinase
Olga Goeransson et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Defining the mechanism of activation of AMP-activated protein kinase by the small molecule A-769662, a member of the thienopyridone family
Matthew J. Sanders et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth
Monica Buzzai et al.
CANCER RESEARCH (2007)
Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-β-4-ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia (ALL) cells:: implication for targeted therapy
Tapas K. Sengupta et al.
MOLECULAR CANCER (2007)
Pharmacologic inhibitors of extracellular signal-regulated kinase (ERKs) and c-Jun NH2-terminal kinase (JNK) decrease glutathione content and sensitize human promonocytic leukemia cells to arsenic trioxide-induced apoptosis
Adrian M. Ramos et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2006)
Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts
Kimberley Hatfield et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Altered glucose metabolism in childhood pre-B acute lymphoblastic leukaemia
J. M. Boag et al.
LEUKEMIA (2006)
Glycolysis inhibition for anticancer treatment
H. Pelicano et al.
ONCOGENE (2006)
Identification and characterization of a small molecule AMPK activator that treats key components of type 2 diabetes and the metabolic syndrome
Barbara Cool et al.
CELL METABOLISM (2006)
Optimizing cancer radiotherapy with 2-deoxy-D-glucose - Dose escalation studies in patients with glioblastoma multiforme
DH Singh et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2005)
Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme
S Oudard et al.
JOURNAL OF NEURO-ONCOLOGY (2003)
Acadesine activates AMPK and induces apoptosis in B-cell chronic lymphocytic leukemia cells but not in T lymphocytes
C Campàs et al.
BLOOD (2003)
Lonidamine: Efficacy and safety in clinical trials for the treatment of solid tumors
S Di Cosimo et al.
DRUGS OF TODAY (2003)
Oxygen saturation in the bone marrow of healthy volunteers
JS Harrison et al.
BLOOD (2002)
Mitochondria-targeting drugs arsenic trioxide and lonidamine bypass the resistance of TPA-differentiated leukemic cells to apoptosis
O Sordet et al.
BLOOD (2001)
Paclitaxel, cisplatin and lonidamine in advanced ovarian cancer. A phase II study
M De Lena et al.
EUROPEAN JOURNAL OF CANCER (2001)
Share Paper
